World News Initiates Coverage on Evoke Pharma (NASDAQ:EVOK) Initiates Coverage on Evoke Pharma (NASDAQ:EVOK) assumed coverage on shares of Evoke Pharma (NASDAQ:EVOK – Free Report) in a report published on Friday. The firm issued a sell rating on the specialty pharmaceutical company’s stock.

Evoke Pharma Stock Performance

Shares of EVOK stock opened at $1.25 on Friday. Evoke Pharma has a 52-week low of $0.92 and a 52-week high of $5.96. The company has a debt-to-equity ratio of 9.29, a quick ratio of 3.27 and a current ratio of 3.50. The firm has a market capitalization of $4.18 million, a PE ratio of -0.55 and a beta of 0.28. The stock has a fifty day simple moving average of $1.20 and a two-hundred day simple moving average of $1.48.

About Evoke Pharma

(Get Free Report)

Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.

Read More

Receive News & Ratings for Evoke Pharma Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Evoke Pharma and related companies with’s FREE daily email newsletter.

Fort Solis: A Beautiful Narrative Experience Hindered by Gameplay


Investigative journalist, David Hundeyin detained in Zimbabwe


CBN deputy governor Obiora reportedly arrested by DSS